Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Clinical trial NCT04968964 · RECRUITING
Trial details
- NCT number
- NCT04968964
- Sponsor
- Washington University School of Medicine
- Status
- RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-07
- Primary completion
- 2028-08-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.